InSTAR Program, Schizophrenia & Metabolic Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
InSTAR Program, Schizophrenia & Metabolic Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Asian J Psychiatr. 2017 Aug;28:142-145. doi: 10.1016/j.ajp.2017.04.005. Epub 2017 Apr 14.
Despite its superior efficacy, clozapine is an underutilized agent, primarily owing to the "Clozaphobia"-fear of clozapine's adverse effects. Emergent cautions on metabolic side-effects have contributed to avoidance of clozapine prescription. Here, we describe our clinical experience with nine patients having schizophrenia/schizoaffective disorders with comorbid diabetes mellitus and treated with clozapine. Interestingly, all patients could be maintained on optimal glycemic control even after clozapine. In conclusion, a critique on the potential risks versus benefits of clozapine amidst our observations from this case series adds further supporting evidence to the emerging literature on the clinical utility of clozapine in treating schizophrenia patients with diabetes mellitus.
尽管氯氮平具有优越的疗效，但它的应用却很有限，主要是因为人们担心氯氮平的不良反应，即“氯氮平恐惧症”。由于对代谢副作用的紧急警告，导致氯氮平的处方被回避。在这里，我们描述了我们对 9 名患有合并糖尿病的精神分裂症/分裂情感障碍患者的临床经验，这些患者接受了氯氮平治疗。有趣的是，所有患者在接受氯氮平治疗后都能保持最佳的血糖控制。总之，从我们的病例系列观察中对氯氮平的潜在风险与益处进行评估，为氯氮平治疗合并糖尿病的精神分裂症患者的临床应用提供了更多的支持证据。
